当前位置： SCI文献检索 > CANCER GENE THERAPY期刊下所有文献 > Induction of systemic antitumor immunity by gene transfer of mammalian heat shock protein 70.1 into tumors in situ.

Induction of systemic antitumor immunity by gene transfer of mammalian heat shock protein 70.1 into tumors in situ.

Abstract：

:Heat shock proteins (hsps) chaperone cytosolic peptides, forming complexes that stimulate antitumor immunity. Hsps facilitate signal 1 in the two-signal model of T-cell costimulation, whereas cell adhesion molecules such as B7.1 provide secondary (signal 2) costimulatory signals. B7.1 gene transfer into tumors in situ has been shown to eradicate small (<0.3 cm in diameter) tumors in mice, and induce systemic antitumor immunity, but is ineffective against larger tumors. We examine whether mammalian hsps, as facilitators of T-cell costimulation, also exhibit this ability, and whether simultaneously stimulating both signal 1 (hsp-facilitated antigen presentation) and signal 2 (B7.1-mediated costimulation) enhances antitumor immunity compared to that achieved with either monotherapy. Prophylactic vaccination of mice with an hsp preparation from an EL-4 lymphoma weakly retarded tumor growth, to the same extent as that achieved with a single EL-4-derived peptide (AQHPNAELL), previously shown to induce antitumor immunity establishing that a preparation of EL-4 hsp-peptide complexes has antitumor activity. Here we show that injection of rat hsp70.1 into mouse tumors in situ causes the complete eradication of tumors, and generates potent systemic antitumor immunity mediated by CD4+ and CD8+ T cells. Unexpectedly, simultaneous gene transfer of hsp70.1 and B7.1 compromised the efficacy of hsp-mediated tumor rejection--a problem which could be partially overcome by the timed delivery of hsp70.1 and B7.1. Thus, gene transfer of hsp70 into tumors can be employed to generate potent systemic antitumor immunity, but further consideration is required if this approach is to be successfully combined with immunotherapies employing other T-cell costimulators.

journal_name

Cancer Gene Ther

journal_title

Cancer gene therapy

authors

Rafiee M,Kanwar JR,Berg RW,Lehnert K,Lisowska K,Krissansen GW

doi

10.1038/sj.cgt.7700395

subject

Has Abstract

pub_date

2001-12-01 00:00:00

pages

974-81

issue

12

eissn

0929-1903

issn

1476-5500

journal_volume

8

pub_type

杂志文章

相关文献

CANCER GENE THERAPY文献大全
  • Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference.

    abstract：:RNA interference (RNAi) is a natural cellular regulatory process that inhibits gene expression by transcriptional, post-transcriptional and translational mechanisms. Synthetic approaches that emulate this process (small interfering RNA (siRNA), short hairpin RNA (shRNA)) have been shown to be similarly effective in th...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2010.35

    authors： Rao DD,Maples PB,Senzer N,Kumar P,Wang Z,Pappen BO,Yu Y,Haddock C,Jay C,Phadke AP,Chen S,Kuhn J,Dylewski D,Scott S,Monsma D,Webb C,Tong A,Shanahan D,Nemunaitis J

    更新日期：2010-11-01 00:00:00

  • Inhibition of ovarian cancer metastasis by adeno-associated virus-mediated gene transfer of nm23H1 in an orthotopic implantation model.

    abstract：:Ovarian cancer is one of the most threatening malignant tumors in females due to the frequent occurrence of metastasis that precedes diagnosis. The present study explored the possibility of preventing ovarian cancer metastasis by promoting nm23H1 expression through adeno-associated virus (AAV)-mediated gene transfer. ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700899

    authors： Li J,Zhou J,Chen G,Wang H,Wang S,Xing H,Gao Q,Lu Y,He Y,Ma D

    更新日期：2006-03-01 00:00:00

  • Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects.

    abstract：:We examined whether novel cytokines, interleukin (IL)-21 and IL-23, that were expressed in tumors could produce antitumor effects in the inoculated mice. Human pancreatic cancer AsPC-1 cells were retrovirally transduced with murine IL-21 or IL-23 (p19-linked p40) gene (AsPC-1/IL-21, AsPC-1/IL-23) and were injected int...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700630

    authors： Ugai S,Shimozato O,Yu L,Wang YQ,Kawamura K,Yamamoto H,Yamaguchi T,Saisho H,Sakiyama S,Tagawa M

    更新日期：2003-10-01 00:00:00

  • Decidua mesenchymal stem cells migrated toward mammary tumors in vitro and in vivo affecting tumor growth and tumor development.

    abstract：:Mesenchymal stem cells (MSCs) have affinity to tumor sites where they home, affecting their biology and growth. Previously, we have isolated mesenchymal cells from the decidua of the human placenta named as decidua-derived MSCs (DMSCs). The aims of the present study were to investigate the migration capacity of DMSCs ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2012.71

    authors： Vegh I,Grau M,Gracia M,Grande J,de la Torre P,Flores AI

    更新日期：2013-01-01 00:00:00

  • Adenovirus-mediated overexpression of Fas induces apoptosis of gliomas.

    abstract：:Gliomas express a higher amount of Fas than normal brain tissue. It is of interest to know whether expression of the Fas receptor is unfavorable to the antiapoptotic pathways in gliomas. In this study, we introduced the Fas gene via an adenovirus vector (Adeno-Fas) into the A-172, U251, and U-373 MG glioma cell lines,...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700110

    authors： Shinoura N,Ohashi M,Yoshida Y,Kirino T,Asai A,Hashimoto M,Hamada H

    更新日期：2000-02-01 00:00:00

  • Adenovirus-mediated N5 gene transfer inhibits tumor cell proliferation by induction of apoptosis.

    abstract：:Gene therapy designed to initiate apoptotic cell death provides a potentially effective method to treat cancer. A prerequisite for this approach is the identification of genes that function in distinct apoptotic pathways. Although apoptotic pathways initiated by receptors such as tumor necrosis factor receptor-1 are w...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700194

    authors： Yin S,Hung MC,Goodrich DW

    更新日期：2000-07-01 00:00:00

  • Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in BT4C rat glioma model.

    abstract：:Adenovirus (Adv)-mediated herpes simplex virus thymidine kinase (adv/tk) gene therapy combined with ganciclovir (GCV) medication is a promising approach for the treatment of malignant glioma. However, optimal administration and the effect of possible adjuvant treatments have not been fully examined. In the present stu...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700515

    authors： Tyynelä K,Sandmair AM,Turunen M,Vanninen R,Vainio P,Kauppinen R,Johansson R,Vapalahti M,Ylä-Herttuala S

    更新日期：2002-11-01 00:00:00

  • Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function.

    abstract：:CD4+CD25+regulatory T cells (T(reg)) impair anti-tumor and anti-viral immunity. As there are higher T(reg) levels in cancer patients compared with healthy individuals, there is considerable interest in eliminating them or altering their function as part of cancer or viral immunotherapy strategies. The scurfin transcri...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2011.63

    authors： Morse MA,Hobeika A,Serra D,Aird K,McKinney M,Aldrich A,Clay T,Mourich D,Lyerly HK,Iversen PL,Devi GR

    更新日期：2012-01-01 00:00:00

  • microRNA-9-5p regulates the mitochondrial function of hepatocellular carcinoma cells through suppressing PDK4.

    abstract：:Due to the lack of early diagnostic and effective treatment modalities, hepatocellular carcinoma (HCC) is still the most lethal cancer with a high mortality on a global scale. Recent studies have highlighted the key roles of microRNAs (miRs) in HCC development. In the study, we attempted to investigate the potential r...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/s41417-020-00253-w

    authors： Si T,Ning X,Zhao H,Zhang M,Huang P,Hu Z,Yang L,Lin L

    更新日期：2020-11-30 00:00:00

  • Bone marrow stromal cells-derived microRNA-181-containing extracellular vesicles inhibit ovarian cancer cell chemoresistance by downregulating MEST via the Wnt/β-catenin signaling pathway.

    abstract：:Cisplatin (DDP)-based strategies are the first-line treatment for cancers; however, resistance to DDP remains a major obstacle to cancer treatment. The current study set out to investigate the effects of microRNA-181c (miR-181c) on the resistance of ovarian cancer cells to DDP. Ovarian cancer-associated miRs as well a...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/s41417-020-0195-6

    authors： Ruan Z,Lu L,Zhang L,Dong M

    更新日期：2020-07-07 00:00:00

  • Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy.

    abstract：:We demonstrated that enhanced expression of the costimulatory molecules CD80, CD54 and CD48 (designated rF-TRICOM) on target cells, as delivered via a recombinant fowlpox vector, results in an increased state of stimulation of CD8+ T cells, and consequent increased lysis of target cells. CTL studies in conjunction wit...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700741

    authors： Slavin-Chiorini DC,Catalfamo M,Kudo-Saito C,Hodge JW,Schlom J,Sabzevari H

    更新日期：2004-10-01 00:00:00

  • Bacterial vectors for imaging and cancer gene therapy: a review.

    abstract：:The significant burden of resistance to conventional anticancer treatments in patients with advanced disease has prompted the need to explore alternative therapeutic strategies. The challenge for oncology researchers is to identify a therapy which is selective for tumors with limited toxicity to normal tissue. Enginee...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章,评审

    doi：10.1038/cgt.2012.59

    authors： Cronin M,Stanton RM,Francis KP,Tangney M

    更新日期：2012-11-01 00:00:00

  • Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells.

    abstract：:Oncolytic herpes simplex virus (HSV) vectors have been used in early phase human clinical trials as a therapy for recurrent malignant glioblastoma. This treatment proved safe but limited improvements in patient survival were observed. The potency of these vectors might be enhanced by targeting vector infectivity to tu...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2010.22

    authors： Grandi P,Fernandez J,Szentirmai O,Carter R,Gianni D,Sena-Esteves M,Breakefield XO

    更新日期：2010-09-01 00:00:00

  • MicroRNA21 and the various types of myeloid leukemia.

    abstract：:Myeloid leukemia (ML) is heterogeneous cancer classified by abnormal growth of myeloid cells due to genetic aberrations and mutations. It is generally categorized by clonal disorders of hematopoietic stem cells and differentiation. The molecular mechanism behind the myeloid malignancies is not yet known, but recent se...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章,评审

    doi：10.1038/s41417-018-0025-2

    authors： Panagal M,S R SK,P S,M B,M K,Gopinathe V,Sivakumare P,Sekar D

    更新日期：2018-08-01 00:00:00

  • Intrabody targeting vascular endothelial growth factor receptor-2 mediates downregulation of surface localization.

    abstract：:Angiogenesis is among the most important mechanisms that helps cancer cells to survive, grow and undergo metastasis. Therefore, inhibiting angiogenesis will suppress tumor growth. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are believed to be important players of angiogenesis. The goal of this s...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2016.76

    authors： Alirahimi E,Ashkiyan A,Kazemi-Lomedasht F,Azadmanesh K,Hosseininejad-Chafi M,Habibi-Anbouhi M,Moazami R,Behdani M

    更新日期：2017-01-01 00:00:00

  • Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.

    abstract：:Replication-selective oncolytic viruses are being developed for human cancer therapy. We previously developed an attenuated adenovirus (OBP-301, Telomelysin), in which the human telomerase reverse transcriptase promoter element drives expression of E1A and E1B genes linked with an internal ribosome entry site. OBP-301...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2012.57

    authors： Watanabe Y,Hashimoto Y,Kagawa S,Kawamura H,Nagai K,Tanaka N,Urata Y,Fujiwara T

    更新日期：2012-11-01 00:00:00

  • Murine neuroblastoma vaccines produced by retroviral transfer of MHC class II genes.

    abstract：:Malignant tumors express tumor-related antigens, but effective antitumor immunity does not occur in the primary host. One hypothesis is that there is insufficient stimulation of T-cell responses due to ineffective antigen presentation. An approach to overcome these deficiencies is to modify tumor cells to express majo...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：

    authors： Hock RA,Reynolds BD,Tucker-McClung CL,Heuer JG

    更新日期：1996-09-01 00:00:00

  • Enhanced antitumor efficacy of an oncolytic adenovirus armed with an EGFR-targeted BiTE using menstrual blood-derived mesenchymal stem cells as carriers.

    abstract：:Poor tumor targeting of oncolytic adenoviruses (OAdv) after systemic administration is considered a major limitation for virotherapy of disseminated cancers. The benefit of using mesenchymal stem cells as cell carriers for OAdv tumor targeting is currently evaluated not only in preclinical models but also in clinical ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/s41417-019-0110-1

    authors： Barlabé P,Sostoa J,Fajardo CA,Alemany R,Moreno R

    更新日期：2020-05-01 00:00:00

  • Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors.

    abstract：:The ability of viruses to readily infect tumor cells both in vitro and in vivo has resulted in their study as antitumor agents through a variety of strategies. Replicating and conditionally replicating viruses and recombinant viruses encoding genes for toxins and/or prodrugs have been studied for their direct antitumo...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章,评审

    doi：10.1038/sj.cgt.7700538

    authors： Mastrangelo MJ,Lattime EC

    更新日期：2002-12-01 00:00:00

  • A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance.

    abstract：:Thymidylate synthase (TS) catalyzes de novo production of thymidylate for DNA synthesis and cell proliferation. As such, TS has been a target of antitumor chemotherapy for many years. Our laboratory has identified several antisense oligodeoxynucleotides (ODNs) that downregulate TS mRNA and protein, inhibit cell prolif...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700566

    authors： Berg RW,Ferguson PJ,Vincent MD,Koropatnick DJ

    更新日期：2003-04-01 00:00:00

  • Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors.

    abstract：:In this study, we investigated the safety and efficacy in cancer patients of a single intra-tumor injection of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene (AdV/TK) followed by systemic administration of ganciclovir (GCV). In 18 patients with malignant tumors refractory to standard...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2009.19

    authors： Xu F,Li S,Li XL,Guo Y,Zou BY,Xu R,Liao H,Zhao HY,Zhang Y,Guan ZZ,Zhang L

    更新日期：2009-09-01 00:00:00

  • Infiltration of dendritic cells and T lymphocytes predicts favorable outcome in epithelial ovarian cancer.

    abstract：:We aimed to analyze the association between the distribution of dendritic cells (DC) with expression of tumor-infiltrating T lymphocytes and clinicopathologic parameters with prognosis in epithelial ovarian cancer (EOC). Thirty-three EOC patient samples were surgically resected, and pathology was examined for clinicop...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2015.7

    authors： Zhang Z,Huang J,Zhang C,Yang H,Qiu H,Li J,Liu Y,Qin L,Wang L,Hao S,Zhang F,Wang X,Shan B

    更新日期：2015-03-01 00:00:00

  • Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.

    abstract：:B-cell malignancies upregulate the B-cell lymphoma 2 (Bcl-2) family inhibitors of the intrinsic apoptosis pathway, making them therapy resistant. However, small-molecule inhibitors of Bcl-2 family members such as ABT-737 restore a functional apoptosis pathway in cancer cells, and its oral analog ABT-263 (Navitoclax) h...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2013.35

    authors： Karlsson H,Lindqvist AC,Fransson M,Paul-Wetterberg G,Nilsson B,Essand M,Nilsson K,Frisk P,Jernberg-Wiklund H,Loskog A

    更新日期：2013-07-01 00:00:00

  • Clinical characteristics and prognostic analysis of multiple primary malignant neoplasms in patients with lung cancer.

    abstract：:Retrospective analysis of data from 14,528 lung cancer patients with multiple primary malignant neoplasm (MPMN) revealed that 2.5% (364/14,528) were MPMN cases and 96.2% (350/364) were diagnosed with two primary malignancies, 3.6% (13/364) with three primary malignancies, and 0.3% (1/364) with four primary malignancie...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/s41417-019-0084-z

    authors： Wang H,Hou J,Zhang G,Zhang M,Li P,Yan X,Ma Z

    更新日期：2019-11-01 00:00:00

  • RNA interference and potential therapeutic applications of short interfering RNAs.

    abstract：:RNA interference is an endogenous gene-silencing mechanism that involves double-stranded RNA-mediated sequence-specific mRNA degradation. The discovery of this pathway together with the elucidation of the structure and function of short interfering RNAs--the effector molecules of RNA interference--has had an enormous ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章,评审

    doi：10.1038/sj.cgt.7700857

    authors： Karagiannis TC,El-Osta A

    更新日期：2005-10-01 00:00:00

  • Molecular conjugate vectors mediate efficient gene transfer into gastrointestinal epithelial cells.

    abstract：:Transfer of genes to the gastrointestinal epithelium would be advantageous from investigational and therapeutic standpoints. Efficient transfer of DNA to the intestinal epithelial cells, however, has been problematic with conventional viral and nonviral vectors. As an alternative, we have utilized molecular conjugate ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：

    authors： Batra RK,Berschneider H,Curiel DT

    更新日期：1994-09-01 00:00:00

  • Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy?

    abstract：:MicroRNAs (miRNAs) were discovered more than a decade ago as noncoding, single-stranded small RNAs (approximately 22 nucleotides) that control the timed gene expression pattern in Caenorhabditis elegans life cycle. A number of these evolutionarily conserved, endogenous miRNAs have been shown to regulate mammalian cell...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章,评审

    doi：10.1038/cgt.2008.8

    authors： Tong AW,Nemunaitis J

    更新日期：2008-06-01 00:00:00

  • Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53).

    abstract：:The immune responses of 10 patients with advanced non-small cell lung cancer receiving monthly intratumoral injections of a recombinant adenovirus containing human wild-type p53 (Ad-p53) to adenovirus and transgene antigens were studied. The predominate cellular and humoral immune responses as measured by lymphocyte p...

    journal_title：Cancer gene therapy

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.cgt.7700138

    authors： Yen N,Ioannides CG,Xu K,Swisher SG,Lawrence DD,Kemp BL,El-Naggar AK,Cristiano RJ,Fang B,Glisson BS,Hong WK,Khuri FR,Kurie JM,Lee JJ,Lee JS,Merritt JA,Mukhopadhyay T,Nesbitt JC,Nguyen D,Perez-Soler R,Pisters KM,P

    更新日期：2000-04-01 00:00:00

  • Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNα/Syn3 treatment in a phase l study.

    abstract：:A phase l study using intravesical Ad-IFNαSyn3 for patients with bacillus Calmette-Guérin-resistant superficial bladder cancer showed a complete remission (CR) of 43% at 90 days after treatment with high levels of interferon-α (IFNα) being produced. Ad-IFNα kills bladder cancer cells by two apoptotic and one necrotic ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2014.1

    authors： Benedict WF,Fisher M,Zhang XQ,Yang Z,Munsell MF,Dinney CN

    更新日期：2014-03-01 00:00:00

  • Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses.

    abstract：:Oncolytic virotherapy using adenoviruses has potential therapeutic benefits for a variety of cancers. We recently developed MOA5, a tumor-specific midkine promoter-regulated oncolytic vector based on human adenovirus serotype 5 (Ad5). We modified the binding tropism of MOA5 by replacing the cell-binding domain of the ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2014.7

    authors： Takagi-Kimura M,Yamano T,Tagawa M,Kubo S

    更新日期：2014-03-01 00:00:00